NewsRx

Search our medical news database

Industry News (Clinical Trials)

Three New In Vivo Gene Therapy Trials Initiated

Published in Cancer Weekly, November 20th, 1995

Introgen Therapeutics, Inc., Austin, Texas, announced that researchers at the University of Texas M.D. Anderson Cancer Center, Houston, have initiated three new in vivo gene therapy studies for the treatment of cancer.

Introgen, which maintains a broad, exclusive license to numerous technologies developed by key scientists at M.D. Anderson, now has the largest in vivo cancer portfolio in the field of gene therapy.

The study researchers have injected the first patients ever with a p53/adenoviral gene therapy product for the treatment of non-resectable and resectable head and neck cancer and non-small cell lung cancer (NSCLC).

"Our...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook